← Back to headlines
Disappointing trial results impact Regeneron Pharmaceuticals in Q2
Regeneron Pharmaceuticals (REGN) experienced a setback in its second quarter due to disappointing results from recent clinical trials, affecting its financial performance.
13 Jul, 14:33 — 13 Jul, 14:33
Sources
Showing 1 of 1 sources
Related Stories
FDA Approves Groundbreaking New Treatment for Pancreatic Cancer
42m ago
Nutritionists Explain How Dietary Fiber Can Improve Sleep Quality
49m ago
Busy Philipps Reveals Rare Brain Tumor Diagnosis and Two Surgeries
1h ago
Closing Arguments Approach in Murder Trial of Mother Accused of Killing Three Children
1h ago